Why the study?
Does a step-therapy program for ARBs reduce antihypertensive drug costs and alter utilization patterns in patients newly starting ACEI or ARB therapy?
Does a step-therapy program for ARBs reduce antihypertensive drug costs and alter utilization patterns in patients newly starting ACEI or ARB therapy?
A step-therapy program requiring ACEI use before ARBs significantly reduced ARB utilization and lowered antihypertensive drug costs by approximately $44 per patient annually.
Authors
No takes yet. Share an insight, caveat, or question.
Supports managed-care cost reduction via ARB step-therapy; leaves open generalizability and effects on adherence or outcomes.
Yokoyama et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: